MMTV-NEU-NDL-YD5 TUMOR AND BENIGN LCMS
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Mammary Gland Tumor Cell, Mammary Gland
DISEASE(S): Breast Cancer
SUBMITTER: 
Sara Frangos
LAB HEAD: Graham Holloway
PROVIDER: PXD071897 | Pride | 2026-05-05
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Jan_26_2024_MSF_430_1_Ben1.raw | Raw | |||
| Jan_26_2024_MSF_430_1_Ben2.raw | Raw | |||
| Jan_26_2024_MSF_430_1_Ben3.raw | Raw | |||
| Jan_26_2024_MSF_430_1_Ben4.raw | Raw | |||
| Jan_26_2024_MSF_430_1_Ben5.raw | Raw |
Items per page: 5 1 - 5 of 11 |
Similar Datasets
Project description:An efficient degradation-based proteomics workflow was established using data-independent acquisition-mass spectrometry (DIA-MS) and the Orbitrap Astral platform to investigate the mode of actions (MOA) and on target specificity of bromodomain and extra-terminal (BET) protein-targeting PROTACs, MZ1 and dBET6. Human cancerous and noncancerous cell lines (HeLa, MDA-MB-231 and HEK293) were treated with 1 µM of the PROTACs and their respective negative control controls (cis-MZ1 and dBET6Me) for 1 h and 24 h. Following treatment, cell pellets were harvested, proteins were processed and analysed in a 96-well plate format to identify proteins dysregulated at each timepoint. This approach successfully identified the three BET family members, bromodomain containing proteins 2/3/4 (BRD2, BRD3, BRD4) as the primary targets of MZ1 and dBET6 from the total proteomes of 9,641, 8,157 and 8,988 quantified proteins in HEK293, HeLa and MDA-MB-231 cells, respectively, after short (1 h) treatment. Extended treatment (24 h) with MZ1 and dBET6 further revealed 51, 57 and 115 secondary proteins significantly perturbed (|log2 fold change (log2FC)| ≥ 1 and adjusted p (adj.p) ≤ 0.05) in HEK293, HeLa and MDA-MB-231 cells, respectively. Overall, this work demonstrates the feasibility of the developed approach for identifying direct PROTAC targets following short incubations, as well as elucidating downstream proteomic alterations upon prolonged treatment, surpassing the resolution achievable by traditional immunoblotting techniques.
2026-03-05 | PXD069438 | Pride
Project description:About 50% of colorectal cancer patients develop liver metastases. Patients with metastatic colorectal cancer have 5-year survival rates below 20% despite new therapeutic regimens. Tumor heterogeneity has been linked with poor clinical outcome, but was so far mainly studied via bulk genomic analyses. In this study we performed spatial proteomics via MALDI mass spectrometry imaging on six patient matched CRC primary tumor and liver metastases to characterize interpatient, intertumor and intratumor hetereogeneity. We found several peptide features that were enriched in vital tumor areas of primary tumors and liver metastasis and tentatively derived from tumor cell specific proteins such as annexin A4 and prelamin A/C. Liver metastases of colorectal cancer showed higher heterogeneity between patients than primary tumors while within patients both entities show similar intratumor heterogeneity sometimes organized in zonal pattern. Together our findings give new insights into the spatial proteomic heterogeneity of primary CRC and patient matched liver metastases.
2023-02-17 | PXD039409 | Pride
Project description:DNA interstrand crosslinks (ICLs) are highly cytotoxic lesions that block essential cellular processes like replication and transcription. Endogenous ICLs can be induced by reactive aldehydes produced during normal cellular metabolism. Defective repair of these aldehyde-induced ICLs is associated with Fanconi anemia (FA), a cancer predisposition syndrome. We previously showed that acetaldehyde-induced ICLs are repaired by the FA-pathway and a novel excision-independent pathway. Here, we demonstrate that ICLs induced by acrolein, another cellular aldehyde, are also repaired by both pathways, establishing the generality of aldehyde ICL repair. Focusing on the FA pathway, we identify DNA polymerase kappa (Polκ) as the primary translesion synthesis (TLS) polymerase responsible for the insertion step during lesion bypass of unhooked aldehyde ICLs. This function requires Polκ's catalytic activity and PCNA interaction domains but is independent of Rev1 interaction. In contrast, Polκ has a minor non-catalytic role in the extension step of cisplatin ICL repair that is dependent on Rev1 interaction. Our work reveals a key role for Polκ in aldehyde ICL repair and provides mechanistic insights into how different ICL structures determine the choice of TLS polymerases during repair.
2025-09-29 | PXD066315 | Pride
Project description:The interaction between Aspergillus fumigatus (Af) spores and the respiratory epithelium, as well as its impact on the epithelial barrier function, remain largely unknown. The respiratory epithelial barrier protects the respiratory epithelium against viral infections. However, it can be compromised by environmental contaminants such as pollen, thereby increasing susceptibility to respiratory viral infections, including alphaherpesvirus equine herpesvirus type 1 (EHV-1). To determine whether Af spores disrupt the epithelial integrity and enhance susceptibility to viral infections, equine respiratory mucosal ex vivo explants were pretreated with Af spore diffusate, followed by EHV-1 inoculation. Af spore proteases were characterized by zymography and identified using mass spectrometry-based proteomics. Proteases of the serine protease, metalloprotease and aspartic protease groups were identified. Morphological analysis of hematoxylin-eosin (HE)-stained sections of the explants revealed that Af spores induced desquamation of epithelial cells and a significant increase in intercellular space at high and low concentrations, respectively. The increase in intercellular space in the epithelium caused by Af spore proteases correlated with an increase in EHV-1 infection. Together, our findings demonstrate that Af spore proteases disrupt epithelial integrity, potentially leading to increased viral infection of the respiratory epithelium.
2024-08-14 | PXD053508 | Pride
Project description:We performed 10X Visium on consecutive 10 µm sections from 8 human NSCLC tumours (total 20 sections), 8 adjacent non-involved lung tissues (total 16 sections) and two healthy donors (total 4 sections)
2024-04-29 | E-MTAB-13530 | biostudies-arrayexpress
Project description:Introduction: MicroRNAs (miRNAs) are small non-coding RNA that play a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of tissue and serum to correlate miRNA expression with clinico-pathological features and patient outcomes. Methods: Tissue and serum samples were collected from patients with locally advanced breast cancer undergoing NAC at four time points: time of diagnosis, after the first and fourth cycle of doxorubicin/cyclophosphamide treatment, and after the fourth cycle of docetaxel administration. First, we evaluated the miRNA expression profiles in tissue and correlated expression with clinico-pathological features. Then, a panel of four miRNAs (miR-451, miR-3200, miR-21, and miR-205) in serum samples was further validated using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). The alterations in serum levels of miRNA, associations with clinical and pathological responses, correlation with clinico-pathological features, and survival outcomes were studied using Friedman, Mann-Whitney U, Spearman, Wilcoxon signed-ranks tests. Pâ¤0.05 was considered statistically significant. Results: We analyzed 32 tissue samples and 108 serum samples from 8 patients and 27 patients, respectively. MicroRNA expression profiling of tumor versus normal tissue revealed more than 100 differentially expressed miRNAs. Serum miR-451 levels were significantly decreased during treatment, and higher serum levels were associated with improved clinical and pathological responses and disease-free survival. The serum levels of miR-3200 declined during NAC, and higher serum levels were associated with lower residual breast cancer burden and relapse rates. Conclusion: Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. Serum and tissue from a total of 27 consecutive patients diagnosed with locally advanced breast cancer undergoing NAC treatment were collected however microarray data were generated from tissue biopsy of 5 patients at four timepoints for both Normal and tumor. Additionally 3 tissue from only tumor at four timepoints and 6 patients at two timepoint T1 and T4
2015-10-31 | E-GEOD-70754 | biostudies-arrayexpress
Project description:Isolation of EVs from complex biofluids plasma and urine using the filter-aided EV enrichment strategy in combination with TWEEN-20 washes
2025-05-07 | PXD056479 | Pride
Project description:To investigate DPPA2/4 bound proteins on chromatin we performed rapid immunoprecipitation mass spectrometry (RIME) following double crosslinking of chromatin in NCI-H661 non-small cell lung cancer cells clonal cell lines (Wild Type clones c51 & c52, DPPA2 knockout clones c41 & c42, DPPA4 knockout clones c78 & c79 as well as DPPA2+4 double knockout clones c08 & c14).
2026-03-31 | PXD070627 | Pride
Project description:We performed 10X Visium on two consecutive 10 µm sections from 11 Ts21 foetal livers and five healthy foetal livers.
2024-07-17 | E-MTAB-13062 | biostudies-arrayexpress
Project description:Using nanoparticles based plasma enrichment strategies on plasma samples, we were able to achieve a huge increase of identified plasma proteins from around 700 to more than 5000 proteins as compared to neat plasma digest. The substantial increase in depth allowed us to perform in-depth analysis and we were able to apply this to a small cohort of plasma samples from pancreatic cancer (PC) patients with primary tumor, tumor that had metastases vs healthy controls. Majority of identified proteins were part of the Human Plasma Proteome Project (HPPP) database, and more than 300 proteins are on the list of FDA approved drug targets. We showed a large and significant increase in ribosomal proteins in plasma of PC that metastasized. ADH1C and ADH1B, both members of the alcohol dehydrogenase family, had one of the largest increase and potentially correlated with liver metastasis. We further highlighted 15 different potentially secreted and/or cell surface proteins that were otherwise not identified in neat, digested plasma and have potential to be useful markers due to their cancer associations. Lastly, we compared different mass spectrometer (Orbitrap Astral and Orbitrap Ascend) and column (depth and throughput) setups on the same dataset and showed similar conclusions potentially can be achieved, although the depth approach on the newer instrumentations can reveal additional insights in the plasma proteome.
2025-12-03 | PXD065103 | Pride